The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies/ 中华急诊医学杂志

Q4 Nursing

中华急诊医学杂志 Pub Date : 2020-02-02 DOI:10.3760/CMA.J.ISSN.1671-0282.2020.0001

Hua Jiang, Hongfei Deng, Yu Wang, Zhan Liu, M. Sun, Ping Zhou, Qingan Xia, C. Lu, J. Zeng

{"title":"The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies/ 中华急诊医学杂志","authors":"Hua Jiang, Hongfei Deng, Yu Wang, Zhan Liu, M. Sun, Ping Zhou, Qingan Xia, C. Lu, J. Zeng","doi":"10.3760/CMA.J.ISSN.1671-0282.2020.0001","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia by systematically review earlier coronavirus studies. \n \n \nMethods \nSystematically retrieve relevant clinical studies from Chinese and English databases such as CNKI,VIP, Wangfang Data,CBM,PubMed, Web of Science,EMBASE. In addition, information from Chinese bio-medical journals, WHO, US CDC, Chinese CDC websites and the references from published relevant articles were retrieved. The inclusion period is from January 2003 to January 24, 2020. The criteria for inclusion are: (1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4) data from multiple reports but originated from one study, where we extract information from all reports; (5) guidelines, includes: national or academic guidelines/experts 'consensus. The exclude criteria are: 1) only have abstracts but no full information; 2) in vitro studies. Two reviewers independently review articles and extract data on study design, patients, diagnosis criteria, regimen, and clinical outcomes (mortality, morbidity, quality of life, steroids dosage, chest image and adverse responses). \n \n \nResults \nTwo hundred and thirty potential article were found by screening, and narrow down to forty-four articles for evaluation and finally four studies were included. The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing. \n \n \nConclusions \nILPV/r can be used as a component of experimental regimen for treat 2019-nCoV pneumonia. It strongly suggests that initiating real world studies to explore the true clinical effects of LPV/r on 2019-nCoV patients. \n \n \nKey words: \n2019-nCoV; Lopinave/Litonawe (LPV/r); S`Anti-virus regimen; Systematical review; Real world study","PeriodicalId":9981,"journal":{"name":"中华急诊医学杂志","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华急诊医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1671-0282.2020.0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 18

Abstract

Objective To explore the possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia by systematically review earlier coronavirus studies. Methods Systematically retrieve relevant clinical studies from Chinese and English databases such as CNKI,VIP, Wangfang Data,CBM,PubMed, Web of Science,EMBASE. In addition, information from Chinese bio-medical journals, WHO, US CDC, Chinese CDC websites and the references from published relevant articles were retrieved. The inclusion period is from January 2003 to January 24, 2020. The criteria for inclusion are: (1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4) data from multiple reports but originated from one study, where we extract information from all reports; (5) guidelines, includes: national or academic guidelines/experts 'consensus. The exclude criteria are: 1) only have abstracts but no full information; 2) in vitro studies. Two reviewers independently review articles and extract data on study design, patients, diagnosis criteria, regimen, and clinical outcomes (mortality, morbidity, quality of life, steroids dosage, chest image and adverse responses). Results Two hundred and thirty potential article were found by screening, and narrow down to forty-four articles for evaluation and finally four studies were included. The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing. Conclusions ILPV/r can be used as a component of experimental regimen for treat 2019-nCoV pneumonia. It strongly suggests that initiating real world studies to explore the true clinical effects of LPV/r on 2019-nCoV patients. Key words: 2019-nCoV; Lopinave/Litonawe (LPV/r); S`Anti-virus regimen; Systematical review; Real world study

查看原文本刊更多论文

使用洛匹那韦/利托那韦（LPV/r）治疗新型冠状病毒2019-nCov肺炎的可能性：基于早期冠状病毒临床研究的快速系统综述/中华急诊医学杂志

目的通过系统回顾早期冠状病毒研究，探讨洛匹那韦/利托那韦（LPV/r）治疗新型冠状病毒2019-nCov肺炎的可能性。方法系统检索CNKI、VIP、望方数据、CBM、PubMed、Web of Science、EMBASE等中英文数据库中的相关临床研究。此外，检索了中国生物医学杂志、世界卫生组织、美国疾控中心、中国疾控中心网站的信息以及已发表的相关文章的参考文献。纳入期为2003年1月至2020年1月24日。纳入标准为：（1）旨在比较LPV/r和安慰剂/标准治疗SARS、MERS的研究；（2）包括至少一个临床结果的研究；（3）诊断标准符合世界卫生组织对SARS或MERS的要求的研究；（4）数据来自多份报告，但来源于一项研究，我们从所有报告中提取信息；（5）指导方针，包括：国家或学术指导方针/专家共识。排除标准是：1）只有摘要，没有完整的信息；2）体外研究。两名评审员独立审查文章，并提取有关研究设计、患者、诊断标准、方案和临床结果（死亡率、发病率、生活质量、类固醇剂量、胸部图像和不良反应）的数据。结果筛选出230篇潜在文章，筛选出44篇进行评价，最终纳入4项研究。纳入研究的结果表明，早期使用LPV/r方案可以降低SARS和MERS的死亡率，并减少类固醇的剂量。结论ILPV/r可作为治疗2019-nCoV肺炎的实验方案的组成部分。这强烈建议启动现实世界研究，探索LPV/r对2019-nCoV患者的真实临床影响。关键词：2019-nCoV；洛匹那韦/利托那韦（LPV/r）；S`抗病毒方案；系统审查；真实世界研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华急诊医学杂志 Nursing-Emergency Nursing

CiteScore

0.10

自引率

0.00%

发文量

8629

期刊介绍： Chinese Journal of Emergency Medicine is the only national journal which represents the development of emergency medicine in China. The journal is supervised by China Association of Science and Technology, sponsored by Chinese Medical Association, and co-sponsored by Zhejiang University. The journal publishes original research articles dealing with all aspects of clinical practice and research in emergency medicine. The columns include Pre-Hospital Rescue, Emergency Care, Trauma, Resuscitation, Poisoning, Disaster Medicine, Continuing Education, etc. It has a wide coverage in China, and builds up communication with Hong Kong, Macao, Taiwan and international emergency medicine circles.